aTyr Pharma ATYR Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan

Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan at other companies

Lifevantage CorporationLFVN

$84K-42.9%

Biodesix, Inc.BDSX

$354K+13.1%

Biodesix, Inc.BDSX

$354K+13.1%

Revolution Medicines, Inc.RVMD

$3.39M+81.9%

Iovance Biotherapeutics, Inc.IOVA

$839K-39.6%

Iovance Biotherapeutics, Inc.IOVA

$839K-39.6%

FAQ

What is aTyr Pharma's proceeds from issuance of common stock under employee stock purchase plan?

aTyr Pharma (ATYR) reported proceeds from issuance of common stock under employee stock purchase plan of $29K in Q4 2025.

How has aTyr Pharma's proceeds from issuance of common stock under employee stock purchase plan changed year-over-year?

aTyr Pharma's proceeds from issuance of common stock under employee stock purchase plan decreased by 52.5% year-over-year, from $61K to $29K.

What does proceeds from issuance of common stock under employee stock purchase plan mean?

This metric tracks the cash inflows generated from the sale of common stock to employees through company-sponsored stock purchase plans. It serves as a measure of employee participation in equity ownership and provides a source of capital through internal equity issuance. Investors monitor this to understand the dilution impact and the extent of employee-driven capital funding.